Semaglutide for Post-Smoking Cessation Weight Management
NCT06173778 on ClinicalTrials.gov · last registry update 2026-02-11
Recruiting now, toward 197 participants. Its estimated completion date, 1 July 2026, has passed with no update to the record. Primary outcome, as filed: Change in Body Weight Percent. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- Other
- Enrollment
- 197
- Started
- 2024-04-23
- Primary completion
- 2026-07-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Body Weight Percent
Conditions studied
Obesity · Overweight · Cigarette Smoking
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.